Midatech Pharma PLC Announces Appointment of Nominated and Financial Adviser

Rhea-AI Summary

Midatech Pharma PLC has appointed Strand Hanson Limited as its Nominated and Financial Adviser, effective immediately. Turner Pope Investments will act as the sole broker for the company. Midatech focuses on improving drug delivery technology with several proprietary platforms aimed at enhancing the bio-delivery and biodistribution of medicines. The company holds significant intellectual property with 36 patent families and successful clinical applications, which position it for future growth.

Positive

• Appointment of Strand Hanson Limited as Nominated and Financial Adviser may enhance strategic guidance.
• Turner Pope Investments as sole broker could streamline investor relations.
• Strong intellectual property portfolio with 36 patent families supports long-term growth.

Negative

• None.

ABINGDON, UK / ACCESSWIRE / March 8, 2022 / Midatech Pharma PLC (AIM:MTPH; NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicine, is pleased to announce the appointment of Strand Hanson Limited as the Company's Nominated and Financial Adviser with immediate effect.

Turner Pope Investments (TPI) Ltd will be the Company's sole broker.

For further information, please contact:

Midatech Pharma PLC Stephen Stamp, CEO, CFO Tel: +44 (0) 29 2048 0180 www.midatechpharma.com

Strand Hanson Limited (Nominated and Financial Adviser) James Dance / Matthew Chandler / Rob Patrick Tel: +44 (0)20 7409 3494

Turner Pope Investments (TPI) Ltd (Broker) Andrew Thacker / James Pope (Corporate Broking) Tel: +44(0)20 3657 0050

IFC Advisory Limited (Financial PR and UK Investor Relations) Tim Metcalfe / Graham Herring Tel: +44 (0)20 3934 6630 Email: midatech@investor-focus.co.uk

Edison Group (US Investor Relations) Alyssa Factor Tel: +1 (860) 573 9637 Email: afactor@edisongroup.com

About Midatech Pharma PLC

Midatech Pharma PLC (dual listed on LSE AIM: MTPH; and NASDAQ: MTP) is a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines. The Company combines approved and development medications with its proprietary and innovative drug delivery technologies to provide compelling products that have the potential to powerfully impact the lives of patients.

The Company has developed three in-house technology platforms, each with its own unique mechanism to improve delivery of medications to sites of disease. All of the Company's technologies have successfully entered human use in the clinic, providing important validation of the potential for each platform:

· Q-Sphera™ platform: a disruptive micro-technology used for sustained release to prolong and control the release of therapeutics over an extended period of time (from weeks to months).

· MidaSolve™ platform: an innovative nanotechnology used to dissolve insoluble drugs so that they can be administered in liquid form directly and locally into tumours.

· MidaCore™ platform: a leading-edge nanotechnology used for targeting medications to sites of disease.

The platform nature of the technologies offers the potential to develop multiple drug assets rather than being reliant on a limited number of programmes. Midatech's technologies are supported by 36 patent families including 120 granted patents and an additional 70 patent applications. Midatech's headquarters and R&D facility is in Cardiff, UK. For more information please visit www.midatechpharma.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: Midatech Pharma PLC

View source version on accesswire.com:
https://www.accesswire.com/692017/Midatech-Pharma-PLC-Announces-Appointment-of-Nominated-and-Financial-Adviser

FAQ

What is the significance of Midatech Pharma's new financial adviser, Strand Hanson Limited?

The appointment of Strand Hanson Limited as Nominated and Financial Adviser is expected to enhance Midatech Pharma's strategic guidance and potentially improve investment opportunities.

Who will be the broker for Midatech Pharma following the recent press release?

Turner Pope Investments has been appointed as the sole broker for Midatech Pharma.

What are the main focuses of Midatech Pharma's drug delivery technology?

Midatech Pharma is focused on improving the bio-delivery and biodistribution of medicines through proprietary technologies like Q-Sphera™, MidaSolve™, and MidaCore™.

How robust is Midatech Pharma's intellectual property portfolio?

Midatech Pharma holds 36 patent families with 120 granted patents and an additional 70 pending applications, indicating a strong intellectual property position.